NEUROCRINE BIOSCIENEUROCRINE BIOSCIENEUROCRINE BIOSCIE

NEUROCRINE BIOSCIE

No trades
Buy NB3
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪10.88 B‬CHF
‪210.23 M‬CHF
‪1.59 B‬CHF
‪98.78 M‬
Beta (1Y)
0.61
Employees (FY)
‪1.4 K‬
Change (1Y)
+200 +16.67%
Revenue / Employee (1Y)
‪1.35 M‬CHF
Net income / Employee (1Y)
‪178.36 K‬CHF

About Neurocrine Biosciences, Inc.


CEO
Kyle W. Gano
Headquarters
San Diego
Founded
1992
FIGI
BBG00LVF08S7
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NB3 is featured.

Frequently Asked Questions


The current price of NB3 is 134.825 CHF — it has increased by 7.74% in the past 24 hours. Watch NEUROCRINE BIOSCIE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange NEUROCRINE BIOSCIE stocks are traded under the ticker NB3.
NB3 stock hasn't changed in a week, the last month showed zero change in price, over the last year NEUROCRINE BIOSCIE has showed a 17.48% increase.
We've gathered analysts' opinions on NEUROCRINE BIOSCIE future price: according to them, NB3 price has a max estimate of 166.44 CHF and a min estimate of 104.89 CHF. Watch NB3 chart and read a more detailed NEUROCRINE BIOSCIE stock forecast: see what analysts think of NEUROCRINE BIOSCIE and suggest that you do with its stocks.
NB3 reached its all-time high on May 8, 2024 with the price of 134.825 CHF, and its all-time low was 111.591 CHF and was reached on Jan 3, 2024. View more price dynamics on NB3 chart.
See other stocks reaching their highest and lowest prices.
NB3 stock is 7.19% volatile and has beta coefficient of 0.61. Track NEUROCRINE BIOSCIE stock price on the chart and check out the list of the most volatile stocks — is NEUROCRINE BIOSCIE there?
Today NEUROCRINE BIOSCIE has the market capitalization of ‪10.88 B‬, it has increased by 2.17% over the last week.
Yes, you can track NEUROCRINE BIOSCIE financials in yearly and quarterly reports right on TradingView.
NEUROCRINE BIOSCIE is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
NB3 earnings for the last quarter are 1.05 CHF per share, whereas the estimation was 1.29 CHF resulting in a −18.24% surprise. The estimated earnings for the next quarter are 1.34 CHF per share. See more details about NEUROCRINE BIOSCIE earnings.
NEUROCRINE BIOSCIE revenue for the last quarter amounts to ‪527.19 M‬ CHF, despite the estimated figure of ‪509.00 M‬ CHF. In the next quarter, revenue is expected to reach ‪543.28 M‬ CHF.
NB3 net income for the last quarter is ‪58.44 M‬ CHF, while the quarter before that showed ‪39.15 M‬ CHF of net income which accounts for 49.26% change. Track more NEUROCRINE BIOSCIE financial stats to get the full picture.
No, NB3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 31, 2024, the company has ‪1.40 K‬ employees. See our rating of the largest employees — is NEUROCRINE BIOSCIE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEUROCRINE BIOSCIE EBITDA is ‪511.91 M‬ CHF, and current EBITDA margin is 22.05%. See more stats in NEUROCRINE BIOSCIE financial statements.
Like other stocks, NB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEUROCRINE BIOSCIE stock right from TradingView charts — choose your broker and connect to your account.